ClinicalTrials.gg
CompletedNCT05532735Updated Dec 11, 2024

Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion

A Phase 2 interventional study of ANXV in Retinal Vein Occlusion, sponsored by Annexin Pharmaceuticals AB. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-11.

Sponsored by Annexin Pharmaceuticals AB · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2024, 2 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 106 studies in Retinal Vein Occlusion with a site in United States — 6 open to participants now, 10 under way, 1 of them phase 3. Retinal Vein Occlusion · United States.

Enrollment
69th of 90
16 · median 40
Started
2022
with 3 others
Phase 2
16 of 106
1 open now
Registered
96th of 106
by date

Among the 106 studies in Retinal Vein Occlusion with a site in United States, this one is the 69th largest by enrollment of the 90 interventional ones that give a count, is one of 4 that started in 2022, is one of 16 in phase 2, and was the 96th registered.

Retinal Vein Occlusion

289 studies on the registry are indexed under Retinal Vein Occlusion; 32 are open to participants now.

Browse Retinal Vein Occlusion studies →

Open to participants now

6 of the 106 studies in Retinal Vein Occlusion with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Retinal Vein Occlusion studies recruiting now, 13 (72%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Retinal Vein Occlusion with a site in United States, or all of them as a file.
02

Study summary

Open-label, dose ascending safety, tolerability, and proof of concept study to evaluate the use of ANXV (human recombinant Annexin A5) in the treatment of subjects with recently diagnosed Retinal Vein Occlusion.

03

Conditions studied

  • Retinal Vein Occlusion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must have given written (signed and dated), and any authorizations required by local law and be able to comply with all study requirements
  2. Male or female, ≥18 years of age at the time of informed consent
  3. Females must be non-pregnant and non-lactating, and either surgically sterile (e.g., ≥6 weeks post bilateral salpingectomy, bilateral oophorectomy with or without hysterectomy) or (12 months of spontaneous amenorrhea in females > 55years of age or, in females ≤55 years, or 12 months of spontaneous amenorrhea without an alternative medical, or 12 months with an elevated Follicle Stimulating Hormone (FSH) level Males must either be surgically sterile or abstinent*, or if engaged in sexual relations with a female of , the subject or the subject's non-pregnant female partner must use a highly effective method from the time of signing the Informed Consent Form (ICF) until at least 30 days after the last dose of study drug; Refer to Section 10.3 for acceptable methods

    *Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred and usual lifestyle of the subject; periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods). Declaration of abstinence for the duration of a trial and withdrawal are not acceptable methods of contraception (Section 10.3).

  4. Onset of symptoms of Retinal Vein Occlusion within 23 days prior to informed consent
  5. The criterion has been removed
  6. The criterion has been removed
  7. Clear ocular media and adequate pupillary dilation in the Study Eye to permit high quality retinal imaging
  8. Willing to refrain from strenuous exercise/activity (for example heavy lifting, weight training, intense aerobics classes etc.) for at least 72 hours prior to study visits
  9. A negative rapid SARS-CoV-2 (COVID) test on Day 1 prior to initiation of study drug infusion

Exclusion criteria

Exclusion Criteria:

Subjects will not be eligible if they have any of the following criteria:

Study Eye only:

  1. A severe (≥0.9 log, Grade 3+ or worse) Relative Afferent Pupillary Defect (RAPD)
  2. Evidence of deep intraretinal hemorrhage involving the center 1mm of the macula
  3. Evidence of neovascularization
  4. Ocular disorders/additional eye disease, which in the opinion of the Investigator may confound interpretation of study results, compromise protocol assessments or are likely to require intervention during the study, including, but not limited to, atrophy of the retinal pigment epithelium, sub-retinal fibrosis, organized hard exudate plaque, diabetic macular edema, retinal detachment, macular hole, vitreomacular traction, macular epiretinal membrane, clinically significant cataract, vitreal opacities or hemorrhage, glaucoma with documented visual field loss, ischemic optic neuropathy, retinitis pigmentosa or choroidal neovascularization of any cause (e.g., Age-related Macular Degeneration (AMD), ocular histoplasmosis, toxoplasmosis, or pathologic myopia)
  5. Laser photocoagulation in the study eye within the preceding 6 months prior to the Screening Visit
  6. Receipt within the past 6 months prior to the Screening Visit of any intraocular surgery (including refractive surgery, cataract surgery), or intravitreal (IVT) injection, or planned intraocular surgery or procedure during the study, unless approved by Medical Monitor or Sponsor
  7. Recent (6 months) history, or current evidence of ocular herpetic diseases (including herpes simplex virus, varicella zoster or cytomegalovirus), unless approved by Medical Monitor or Sponsor

    Fellow Eye:

  8. BCVA in the Fellow eye of ≤70 ETDRS letters (approximately 20/40 or less), unless approved by the Medical Monitor or the Sponsor

    Both Eyes:

  9. Within 6 months prior to the Screening Visit, use of medications known to be toxic to the retina, lens, or optic nerve (e.g., desferoxamine, chloroquine/hydrochloroquine, chlorpromazine, phenothiazines, tamoxifen, and ethambutol)
  10. Known or allergy to fluorescein (e.g., bronchospasm, rash, etc.) or to any component of the study products or a to dilation of the pupil or fixed pupils; mild allergies without angio-edema or treatment need may be acceptable if deemed not to be of clinical significance (including but not limited to allergy to animals or mild seasonal hay fever)
  11. An IOP greater than 24 mmHg that is not controlled with medication or surgery at the time of the Screening Visit
  12. Recent (6 months) history of, or presence of uveitis, presence of intraocular inflammation (history of blepharitis is not exclusionary), current ocular infection

    General:

  13. Unwillingness or inability to attend all study visits and/or perform all procedures/tests/examinations, including follow-up, as specified by this protocol, or unwillingness to cooperate fully with the Investigator
  14. Any medical or surgical procedure or trauma within 4 weeks prior to the day of Treatment 1 (study drug administration), or planned major surgery within the duration of the study through Day 120, unless approved by Medical Monitor or Sponsor
  15. History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study
  16. Prior exposure to a recombinant Annexin A5
  17. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the Investigator, or history of hypersensitivity to biologics (for example systemically administered recombinant proteins/peptides; a similar drug class to ANXV)
  18. Uncontrolled hypertension (systolic > 180 mmHg or diastolic > 110 mmHg)
  19. Current use of any systemically administered anti-angiogenic agent (e.g., bevacizumab, sunitinib, cetuximab, sorafenib, pazopanib) or , approved or 5 half-lives of agent
  20. Diagnosed untreated systemic
  21. A current systemic infection or inflammation that may require antiviral or antimicrobial therapy that will not be completed prior to Screening Visit, or that in the opinion of the Investigator and with concurrence of the Medical Monitor may either put the subject at risk or may influence the results of the study, or the subject's ability to participate in the study
  22. Treatment with another investigational drug, biological agent, or device within 3 months of Screening Visit, or 5 half-lives of investigational agent, whichever is longer or planned participation in an investigational trial from signing ICF through Day 120
  23. History of thromboembolic events or deep venous thrombosis within 3 months of Screening Visit
  24. Current use of anticoagulant medication (any medications that might have effect on coagulation, hemostasis, and ); low dose aspirin allowed prior to but must be stopped at the time of consent; may begin again 1 day post Treatment 5 infusion
  25. Current daily use of benzodiazepines (intermittent use permissible with Medical Monitor or Sponsor approval)
  26. Clinically significant abnormal coagulation parameters at baseline
  27. The criterion has been removed from the protocol
  28. History of disease with anticipated presence of persistent Annexin A5 antibodies, e.g., antiphospholipid syndrome, systemic lupus erythematosus, rheumatoid arthritis, Behcet disease or systemic sclerosis
  29. Inherited blood disorder (e.g. sickle cell disease, thalassemia)
  30. History of unstable coronary artery disease or cerebrovascular accident within the last 3 months
  31. below 70 mL/min at baseline
  32. Current drug or alcohol abuse, current excessive smoking (i.e., ≥ 20/day)
  33. Known history of or positive test for or chronic
  34. Class III obesity ( ≥ 40kg/m2), at the time of informed consent (Sponsor may accept eligibility for a subject with higher Body Mass Index
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    2 mg ANXV

    ANXV (human recombinant Annexin A5), infusion, 2 mg daily during five days.

    Biological: ANXV

  • Experimental
    4 mg ANXV

    ANXV (human recombinant Annexin A5), infusion, 4 mg daily during five days.

    Biological: ANXV

  • Experimental
    1 mg ANXV

    ANXV (human recombinant Annexin A5), infusion, 1 mg daily during five days.

    Biological: ANXV

  • Experimental
    6 mg ANXV

    ANXV (human recombinant Annexin A5), infusion, 6 mg daily during five days.

    Biological: ANXV

  • Experimental
    8 mg ANXV

    ANXV (human recombinant Annexin A5), infusion, 8 mg daily during five days.

    Biological: ANXV

Interventions

  • BiologicalANXV

    ANXV (Human recombinant Annexin A5 protein)

06

What researchers measure

Primary outcomes

  1. Safety - Treatment Emergent Adverse Events

    Incidence and severity of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: 120 days

  2. Safety - Anti-drug antibodies

    Incidence and titer of anti-drug antibodies (ADA) to ANXV pre- and post-administration

    Time frame: 120 days

Secondary outcomes

  1. Safety - Slit lamp

    Slit-lamp biomicroscopy including intraocular pressure (IOP) and dilated indirect ophthalmoscopy

    Time frame: 120 days

  2. Safety - Gonioscopy

    Time frame: 120 days

  3. Safety - Best Corrected Visual Acuity (BCVA)

    Distance BCVA by manifest refraction should be performed utilizing the ETDRS chart at a starting distance of 4 meters

    Time frame: 120 days

  4. Safety - laboratory parameters

    Concentration of analytes in Chemistry panel, lipid panel, hematology, coagulation, inflammatory and urinalysis

    Time frame: 15 days

  5. Safety - vital signs Blood Pressure

    Blood pressure (BP)

    Time frame: 15 days

  6. Safety - vital signs Heart rate

    Heart rate (HR)

    Time frame: 15 days

  7. Safety - vital signs Weight

    Weight

    Time frame: 15 days

  8. Safety - vital signs Body Temperature

    Body temperature

    Time frame: 15 days

  9. Safety - vital signs Respiratory rate

    Respiratory rate (RR)

    Time frame: 15 days

  10. Safety - vital signs Pulse oximetry

    Pulse oximetry

    Time frame: 15 days

  11. Safety - ECG

    12-lead ECG

    Time frame: 15 days

  12. Safety - ANXV anti-drug antibodies Persistence

    Persistence anti-drug antibodies

    Time frame: 12 months

  13. Safety - ANXV anti-drug antibodies Titer

    Titer of anti-drug antibodies

    Time frame: 12 months

  14. Efficacy - Microperimetry Change from baseline

    Change from baseline in microperimetry mean retinal sensitivity calculated on all stimulus points ≤20 dB at baseline (MSEff), at Days 8, 15, and 29

    Time frame: 120 days

  15. Efficacy - Microperimetry Stimulus points

    Number of microperimetry stimulus points that improve by ≥7decibels (dB) from baseline to Day 8 and 29 after the first ANXV infusion

    Time frame: 120 days

  16. Efficacy - Microperimetry Improvement over baseline

    Number of subjects with an improvement over baseline in MSEff of ≥7dB at Days 8, 15 and 29 (MMP positive responders, MMP-pos)

    Time frame: 120 days

  17. Efficacy - Microperimetry Incremental loss

    Number of subjects with an incremental loss over baseline in MSEff of ≥7dB at Days 8, 15 and 29 (MMP negative responders, MMP-neg)

    Time frame: 120 days

  18. Efficacy - Microperimetry Improvement of ≥7dB

    Number of subjects with an improvement of ≥7dB over baseline in ≥5 stimulus points at Days 8, 15 and 29 (MMP positive-5 responders, MMP-pos-5)

    Time frame: 120 days

  19. Efficacy - Microperimetry MMP negative-5 responders

    Number of MMP negative-5 responders, i.e., subjects with an incremental loss over baseline of ≥7dB in ≥5 stimulus points at Days 8, 15 and 29 (MMP-neg-5)

    Time frame: 120 days

  20. Efficacy - BCVA Improvement

    Number of subjects with an improvement of ≥15 ETDRS letters over baseline at Days 8, 15 and 29

    Time frame: 120 days

  21. Efficacy - BCVA Improvement or letter score ≥78

    Number of subjects with an improvement of ≥15 ETDRS letters over baseline or an ETDRS letters score ≥78 at Days 8, 15 and 29

    Time frame: 120 days

  22. Efficacy - Spectral Domain Optical Coherence Tomography / Spectral Domain Optical Coherence Tomography Angiography (SD-OCT/OCTA) SD-OCT

    Change from baseline in Center Subfield Macular Thickness (CMT), Macular Volume and Outer Nuclear Layer (ONL) thickness on SD-OCT at Days 8, 15 and 29

    Time frame: 120 days

  23. Efficacy - Spectral Domain Optical Coherence Tomography / Spectral Domain Optical Coherence Tomography Angiography (SD-OCT/OCTA) OCTA

    Change from baseline in Foveal Avascular Zone (FAZ) and Vessel Density (VD) on OCTA at Days 8, 15 and 29

    Time frame: 120 days

  24. Efficacy - Ultra-Wide Field Fluorescein Angiography (UWF-FA) Size of Retinal Area of Non-Perfusion

    Change from baseline at Days 8 and 29 in the size of Retinal Area of Non-Perfusion (RANP) for: 1. all the retina captured by UWF-FA 2. in posterior pole

    Time frame: 120 days

  25. Efficacy - Ultra-Wide Field Fluorescein Angiography (UWF-FA) Conversion from non-ischemic RVO to ischemic RVO

    Number of subjects at Days 8, and 29 with: 1. RANP ≥30 DA 2. RANP ≥10 DA Rate of conversion from non-ischemic RVO (niRVO) to ischemic RVO (iRVO) by Day 29

    Time frame: 120 days

  26. Efficacy - Need for rescue treatment with anti Vascular Endothelial Growth Factor (aVEGF) therapy

    Number of subjects requiring rescue with an aVEGF by Day 29

    Time frame: 29 days

  27. Ischemic Index

    Change in Ischemic Index (ISI) from baseline at Days 8 and 29

    Time frame: 120 Days

  28. Pharmacokinetic (PK) profile

    ANXV concentration on Days 1 and 5 pre-infusion and at 15, 30, and 40 minutes and 1, 1.5, 2 and 3.5 hours after the start of the infusion

    Time frame: 5 days

Other outcomes

  1. ANXV binding sites

    Assessment of ANXV binding sites (PS on circulating cells and microparticles) in whole blood sample, Day 1 (pre- infusion), Days 1 and 5 at 5 minutes post infusion, and 3 hours post end of infusion and on Days 8, 15 and 43

    Time frame: 43 days

  2. Endogenous Annexin A5

    Endogenous Annexin A5 levels, Day 1 (pre-infusion) and Days 8, 15 and 43

    Time frame: 43 days

07

Study locations

7 sites
  • Eye Associates of Northeast Louisiana
    West Monroe, Louisiana 71219, United States
  • Cumberland Valley Retina Consultants
    Hagerstown, Maryland 21740, United States
  • Tulsa Retina Consultants
    Tulsa, Oklahoma 74114, United States
  • Retina Consultants of Texas
    Bellaire, Texas 77401, United States
  • Valley Retina Institute
    McAllen, Texas 78503, United States
  • Retina Consultants of Texas
    San Antonio, Texas 78240, United States
  • Virginia Retina Center
    Warrenton, Virginia 20186, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Jul 2024, 22 months.

Of 14 phase 2 interventional studies under Retinal Vein Occlusion, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 29. This study's 22 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2022
First posted
Sep 8, 2022
StartActual
Aug 24, 2022
Primary completionActual
Jul 17, 2024
CompletionActual
Nov 11, 2024
Last update
Dec 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05532735
Lead sponsor
Annexin Pharmaceuticals AB
Collaborators
InFocus Clinical Research
Responsible party
Sponsor
First posted
Sep 8, 2022
Start date
Aug 24, 2022
Primary completion
Jul 17, 2024
Completion
Nov 11, 2024
Last update
Dec 11, 2024

Study contacts

Anna Frostegård
study director · Annexin Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion